Teicoplanin is a potential inhibitor of SARS CoV-2 replication enzymes: A docking study
- Author:
Aatika SADIA
1
;
Muhammad AZAM
1
;
Muhammad Asim Raza BASRA
1
Author Information
- Publication Type:Journal Article
- Keywords: Antibiotics; Antiviral; Molecular docking; Oxicam; SARS CoV-2
- From:Asian Pacific Journal of Tropical Biomedicine 2020;10(12):563-568
- CountryChina
- Language:Chinese
- Abstract: Objective: To explore potential inhibitors of viral enzymes of SARS CoV-2. Methods: The in-silico docked potential of anti-viral, antibiotic, and analgesic drugs were studied for inhibition of the nonstructural protein (NSP) 9, NSP3, and NSP15 of SARS CoV-2 using recent structural peculiarities of these enzymes, 3D optimized structures of drugs and algorithm-based ligand inhibitory potential. Results: Teicoplanin, azithromycin, and remdesivir potentially inhibited NSP9 (Dock-score 9 620, 5 472 and 6 252, respectively), NSP3 (Dock-score 9 846, 5 604 and 5 548, respectively) and NSP15 (Dock-score 10 960, 6414 and 6 002, respectively). Conclusions: Teicoplanin acts as a significant receptor antagonist and potentially inhibits the SARS CoV-2 enzymes.
